BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Imgenex Corporation Now Offers An ELISA Kit To Measure Severe Acute Respiratory Syndrome -SARS- Coronavirus Nucleocapsid Protein


10/19/2005 5:10:54 PM

SAN DIEGO--(BUSINESS WIRE)--April 13, 2004--A leading provider of antibodies against SARS proteins, IMGENEX is proud to offer a sandwich ELISA kit to quantitatively measure the presence of SARS nucleocapsid (SARS-N) protein in infected cells or serum. Thought to be the most prominent protein in culture supernatants infected with SARS virus, the 46-kDa nucleocapsid protein can be detected by anti-nucleocapsid protein antibodies in SARS patients as early as 6 to 10 days post-infection. This suggests the nucleocapsid protein is a major immunogen and may be useful for early diagnosis of SARS infection. A number of PCR-based diagnostic tests are commercially available for detection of the SARS virus; however, very few ELISA kits are available for studying expression of different SARS proteins in experimental systems. At present, this sensitive ELISA kit is available for research use only. "We believe the SARS-N ELISA kit will greatly facilitate research on SARS infection," said Gita Singh, director of Molecular Biology at IMGENEX.

Since its first appearance in November 2002, SARS coronavirus (SARS-CoV), identified as the causative agent of Severe Acute Respiratory Syndrome (SARS), has affected thousands of individuals and become a global concern. Coronaviruses, which are the major cause of upper respiratory tract illness and accounts for as much as 33% of all cases of the common cold, are positive stranded RNA viruses containing one of the largest viral RNA genomes known to date.

About Imgenex

IMGENEX Corp. (www.imgenex.com) with offices at San Diego and Bhubaneswar, India, develops and commercializes novel reagents for the scientific study of human biology and disease and for the production of new diagnostic assays and potential therapies of such diseases. These novel reagents include antibodies, gene and protein expression systems, arrays of various cells and tissues, and siRNA interference systems for use in studies of functional genomics. Areas of biological interest at IMGENEX include cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, and metabolic and infectious diseases.

Contacts

IMGENEX Corp., San Diego Sujay Singh, Ph.D. or Lisa Stein, Ph.D., 858-642-0978 Toll free: 888-723-GENE (4363) Fax: 858-642-0937 ssingh@imgenex.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES